STOCK TITAN

[Form 4] SELECT MEDICAL HOLDINGS CORP Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Insider activity: On 07/29/2025, Select Medical Holdings (SEM) Executive Chairman & Director Robert A. Ortenzio received 250,000 restricted shares at $0. The grant vests in three equal annual installments over the next three years.

Post-transaction, Ortenzio owns 7,081,788 shares directly and 2,120,245 shares indirectly through family trusts, for total exposure of roughly 9.2 million shares. No shares were sold and no options or other derivatives were involved.

The award modestly dilutes shareholders (≈0.18% of SEM’s 136 m shares outstanding) but reinforces insider alignment as the founder increases his stake without cash outflow.

Attività degli insider: Il 29/07/2025, Robert A. Ortenzio, Presidente Esecutivo e Direttore di Select Medical Holdings (SEM), ha ricevuto 250.000 azioni vincolate a prezzo zero. La concessione si acquisisce in tre rate annuali uguali nei prossimi tre anni.

Dopo la transazione, Ortenzio possiede 7.081.788 azioni direttamente e 2.120.245 azioni indirettamente tramite trust familiari, per un'esposizione totale di circa 9,2 milioni di azioni. Non sono state vendute azioni né coinvolte opzioni o altri derivati.

Il premio diluisce modestamente gli azionisti (circa lo 0,18% delle 136 milioni di azioni in circolazione di SEM) ma rafforza l'allineamento degli insider, poiché il fondatore aumenta la sua partecipazione senza esborso di denaro.

Actividad de los insiders: El 29/07/2025, Robert A. Ortenzio, Presidente Ejecutivo y Director de Select Medical Holdings (SEM), recibió 250,000 acciones restringidas a $0. La concesión se otorga en tres cuotas anuales iguales durante los próximos tres años.

Tras la transacción, Ortenzio posee 7,081,788 acciones directamente y 2,120,245 acciones indirectamente a través de fideicomisos familiares, con una exposición total aproximada de 9.2 millones de acciones. No se vendieron acciones ni se involucraron opciones u otros derivados.

El premio diluye modestamente a los accionistas (≈0.18% de las 136 millones de acciones en circulación de SEM) pero refuerza la alineación interna, ya que el fundador aumenta su participación sin desembolso de efectivo.

내부자 활동: 2025년 7월 29일, Select Medical Holdings(SEM)의 집행 의장 겸 이사인 Robert A. Ortenzio는 250,000주 제한 주식을 $0에 받았습니다. 이 주식은 향후 3년 동안 매년 동일한 세 번의 할부로 취득됩니다.

거래 후 Ortenzio는 직접 7,081,788주와 가족 신탁을 통해 간접적으로 2,120,245주를 보유하여 총 약 920만 주의 지분을 가지고 있습니다. 주식은 매도되지 않았으며, 옵션이나 기타 파생상품도 포함되지 않았습니다.

이 보상은 주주 지분을 약간 희석시킵니다(SEM의 1억 3,600만 주 중 약 0.18%) 하지만 창립자가 현금 유출 없이 지분을 늘리면서 내부자와의 이해관계를 강화합니다.

Activité des initiés : Le 29/07/2025, Robert A. Ortenzio, Président exécutif et administrateur de Select Medical Holdings (SEM), a reçu 250 000 actions restreintes à 0 $. La subvention est acquise en trois versements annuels égaux sur les trois prochaines années.

Après la transaction, Ortenzio détient 7 081 788 actions directement et 2 120 245 actions indirectement via des trusts familiaux, pour une exposition totale d'environ 9,2 millions d'actions. Aucune action n'a été vendue et aucune option ou autre dérivé n'a été impliqué.

Cette attribution dilue modestement les actionnaires (≈0,18 % des 136 millions d'actions en circulation de SEM) mais renforce l'alignement des initiés, le fondateur augmentant sa participation sans sortie de trésorerie.

Insider-Aktivität: Am 29.07.2025 erhielt Robert A. Ortenzio, Executive Chairman & Director von Select Medical Holdings (SEM), 250.000 beschränkte Aktien zum Preis von 0 $. Die Zuteilung wird in drei gleichen jährlichen Raten über die nächsten drei Jahre vestet.

Nach der Transaktion hält Ortenzio 7.081.788 Aktien direkt und 2.120.245 Aktien indirekt über Familienstiftungen, was einer Gesamtbeteiligung von etwa 9,2 Millionen Aktien entspricht. Es wurden keine Aktien verkauft und keine Optionen oder andere Derivate verwendet.

Die Zuteilung verwässert die Aktionäre geringfügig (≈0,18 % der 136 Mio. ausstehenden SEM-Aktien), stärkt jedoch die Interessenangleichung der Insider, da der Gründer seine Beteiligung ohne Geldabfluss erhöht.

Positive
  • Founder/executive increases direct ownership by 250,000 shares through a multi-year restricted-stock grant, aligning incentives with shareholders.
  • Dilution is minor (~0.18% of share count), limiting negative impact on existing holders.
Negative
  • None.

Insights

TL;DR: Restricted-stock grant to founder; positive alignment signal, immaterial dilution.

The Form 4 shows Robert A. Ortenzio adding 250 k restricted shares that vest over three years. Because the grant is at no cost and has a multi-year vesting schedule, it ties the Executive Chairman’s incentives closely to long-term performance. Direct holdings rise to 7.1 m shares—about 5.2% of shares outstanding—while total economic exposure tops 9 m. The incremental dilution (~0.18%) is negligible for investors. Historically, insider purchases or awards that increase ownership, especially by founders, are interpreted as a constructive signal. However, because this is a routine equity-compensation action rather than an open-market buy, market impact should be limited.

Attività degli insider: Il 29/07/2025, Robert A. Ortenzio, Presidente Esecutivo e Direttore di Select Medical Holdings (SEM), ha ricevuto 250.000 azioni vincolate a prezzo zero. La concessione si acquisisce in tre rate annuali uguali nei prossimi tre anni.

Dopo la transazione, Ortenzio possiede 7.081.788 azioni direttamente e 2.120.245 azioni indirettamente tramite trust familiari, per un'esposizione totale di circa 9,2 milioni di azioni. Non sono state vendute azioni né coinvolte opzioni o altri derivati.

Il premio diluisce modestamente gli azionisti (circa lo 0,18% delle 136 milioni di azioni in circolazione di SEM) ma rafforza l'allineamento degli insider, poiché il fondatore aumenta la sua partecipazione senza esborso di denaro.

Actividad de los insiders: El 29/07/2025, Robert A. Ortenzio, Presidente Ejecutivo y Director de Select Medical Holdings (SEM), recibió 250,000 acciones restringidas a $0. La concesión se otorga en tres cuotas anuales iguales durante los próximos tres años.

Tras la transacción, Ortenzio posee 7,081,788 acciones directamente y 2,120,245 acciones indirectamente a través de fideicomisos familiares, con una exposición total aproximada de 9.2 millones de acciones. No se vendieron acciones ni se involucraron opciones u otros derivados.

El premio diluye modestamente a los accionistas (≈0.18% de las 136 millones de acciones en circulación de SEM) pero refuerza la alineación interna, ya que el fundador aumenta su participación sin desembolso de efectivo.

내부자 활동: 2025년 7월 29일, Select Medical Holdings(SEM)의 집행 의장 겸 이사인 Robert A. Ortenzio는 250,000주 제한 주식을 $0에 받았습니다. 이 주식은 향후 3년 동안 매년 동일한 세 번의 할부로 취득됩니다.

거래 후 Ortenzio는 직접 7,081,788주와 가족 신탁을 통해 간접적으로 2,120,245주를 보유하여 총 약 920만 주의 지분을 가지고 있습니다. 주식은 매도되지 않았으며, 옵션이나 기타 파생상품도 포함되지 않았습니다.

이 보상은 주주 지분을 약간 희석시킵니다(SEM의 1억 3,600만 주 중 약 0.18%) 하지만 창립자가 현금 유출 없이 지분을 늘리면서 내부자와의 이해관계를 강화합니다.

Activité des initiés : Le 29/07/2025, Robert A. Ortenzio, Président exécutif et administrateur de Select Medical Holdings (SEM), a reçu 250 000 actions restreintes à 0 $. La subvention est acquise en trois versements annuels égaux sur les trois prochaines années.

Après la transaction, Ortenzio détient 7 081 788 actions directement et 2 120 245 actions indirectement via des trusts familiaux, pour une exposition totale d'environ 9,2 millions d'actions. Aucune action n'a été vendue et aucune option ou autre dérivé n'a été impliqué.

Cette attribution dilue modestement les actionnaires (≈0,18 % des 136 millions d'actions en circulation de SEM) mais renforce l'alignement des initiés, le fondateur augmentant sa participation sans sortie de trésorerie.

Insider-Aktivität: Am 29.07.2025 erhielt Robert A. Ortenzio, Executive Chairman & Director von Select Medical Holdings (SEM), 250.000 beschränkte Aktien zum Preis von 0 $. Die Zuteilung wird in drei gleichen jährlichen Raten über die nächsten drei Jahre vestet.

Nach der Transaktion hält Ortenzio 7.081.788 Aktien direkt und 2.120.245 Aktien indirekt über Familienstiftungen, was einer Gesamtbeteiligung von etwa 9,2 Millionen Aktien entspricht. Es wurden keine Aktien verkauft und keine Optionen oder andere Derivate verwendet.

Die Zuteilung verwässert die Aktionäre geringfügig (≈0,18 % der 136 Mio. ausstehenden SEM-Aktien), stärkt jedoch die Interessenangleichung der Insider, da der Gründer seine Beteiligung ohne Geldabfluss erhöht.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Khanuja Parvinderjit S.

(Last) (First) (Middle)
C/O SELECT MEDICAL CORPORATION
4714 GETTYSBURG ROAD

(Street)
MECHANICSBURG PA 17055

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SELECT MEDICAL HOLDINGS CORP [ SEM ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 07/29/2025 A(1) 14,035 A $0 79,124 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Grant of restricted stock which, subject to certain exceptions, will vest in full on July 29, 2026, the first anniversary of the grant date.
/s/ Michael E. Tarvin, Attorney-in-Fact 07/31/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did SEM’s Executive Chairman acquire?

Robert A. Ortenzio received 250,000 restricted shares on 07/29/2025.

What is Ortenzio’s total ownership in SEM after the grant?

He now holds 7,081,788 shares directly plus 2,120,245 indirectly, totaling ≈9.2 million shares.

Does the grant involve cash outlay or option exercise?

No; the shares were granted at $0 under the company’s equity plan.

When will the restricted shares vest?

They vest in three equal annual installments over the next three years.

What is the potential dilution from this issuance?

Approximately 0.18% of SEM’s ~136 million shares outstanding.
Select Medical

NYSE:SEM

SEM Rankings

SEM Latest News

SEM Latest SEC Filings

SEM Stock Data

1.83B
110.06M
14.6%
83.81%
3.47%
Medical Care Facilities
Services-hospitals
Link
United States
MECHANICSBURG